Evidence map›Paper›PMID 30134822›Full record

ArticleMolecular medicine (Cambridge, Mass.)2018

The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.

Anna Mandel, Per Larsson, Martuza Sarwar, Julius Semenas, Azharuddin Sajid Syed Khaja, Jenny L Persson

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anna MandelDepartment of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.
Per LarssonDepartment of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.
Martuza SarwarDivision of Experimental Cancer Research, Department of Translational Medicine, Clinical Research Centre, Lund University, Jan Waldenströms gatan 35, 205 02, Malmö, Sweden.
Julius SemenasDepartment of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.
Azharuddin Sajid Syed KhajaDepartment of Molecular Biology, Umeå University, 901 87, Umeå, Sweden.
Jenny L PerssonDepartment of Molecular Biology, Umeå University, 901 87, Umeå, Sweden. jenny_l.persson@med.lu.se.
Umeå University · SELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic Prostate cancer (PCa) cells have gained survival and invasive advantages. Epidermal growth factor (EGF) receptor is a receptor tyrosine kinase, which may mediate signalling to promote progression and invasion of various cancers. In this study, we uncovered the molecular mechanisms underlying the interconnection among the androgen receptor (AR), matrix metalloproteinase-9 (MMP9) and EGFR in promoting PCa progression.

methodsImmunohistochemical analysis of the tissue microarrays consisting of primary and metastatic PCa tissues was performed. The clinical importance of EGFR and its association with survivals were analyzed using three cohorts from MSKCC Prostate Oncogenome Project dataset (For primary tumors, n = 181; for metastatic tumors n = 37) and The Cancer Genome Atlas Prostate Adenocarcinoma Provisional dataset (n = 495). Targeted overexpression or inhibition of the proteins of interests was introduced into PCa cell lines. Treatment of PCa cell lines with the compounds was conducted. Immunoblot analysis was performed.

resultsWe showed that AR, MMP-9 and EGFR are interconnect factors, which may cooperatively promote PCa progression. Altered EGFR expression was associated with poor disease-free survival in PCa patients. Induced overexpression of AR led to an increase in the expression of EGFR, p-GSK-3β and decrease in p27 expression in PCa cell lines in the presence of androgen stimulation. Overexpression of MMP9 significantly induced EGFR expression in PCa cells. Inhibition of PIP5K1α, a lipid kinase that acts upstream of PI3K/AKT greatly reduced expressions of AR, MMP-9 and EGFR.

conclusionsOur findings also suggest that PCa cells may utilize AR, EGFR and MMP-9 pathways in androgen-dependent as well as in castration-resistant conditions. Our data suggest a new therapeutic potential to block cancer metastasis by targeting AR, EGFR and MMP-9 pathways in subsets of PCa patients.

Indexed as

Cell Line, TumorErbB ReceptorsHumansMaleMatrix Metalloproteinase 9Prostatic NeoplasmsReceptors, AndrogenSignal TransductionAR protein, humanEGFR protein, humanErbB ReceptorsMatrix Metalloproteinase 9MMP9 protein, humanReceptors, AndrogenAndrogen receptor and androgenCancer metastasisEpidermal growth factor receptorProstate cancer

Identifiers

PMID30134822
PMCPMC6020326
OpenAlexW2810608944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.